SK283693B6 - Spôsob prípravy kamptotecínu alebo jeho farmaceuticky prijateľnej soli - Google Patents

Spôsob prípravy kamptotecínu alebo jeho farmaceuticky prijateľnej soli Download PDF

Info

Publication number
SK283693B6
SK283693B6 SK259-93A SK25993A SK283693B6 SK 283693 B6 SK283693 B6 SK 283693B6 SK 25993 A SK25993 A SK 25993A SK 283693 B6 SK283693 B6 SK 283693B6
Authority
SK
Slovakia
Prior art keywords
camptothecin
formula
compound
alkoxy
hydrogen
Prior art date
Application number
SK259-93A
Other languages
English (en)
Slovak (sk)
Other versions
SK25993A3 (en
Inventor
Joseph Marian Fortunak
Antonietta Rose Mastrocola
Mark Mellinger
Jeffery Lee Wood
Patrick Lee Burk
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of SK25993A3 publication Critical patent/SK25993A3/sk
Publication of SK283693B6 publication Critical patent/SK283693B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Auxiliary Devices For And Details Of Packaging Control (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SK259-93A 1990-09-28 1991-09-23 Spôsob prípravy kamptotecínu alebo jeho farmaceuticky prijateľnej soli SK283693B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58964390A 1990-09-28 1990-09-28
PCT/US1991/006888 WO1992005785A1 (fr) 1990-09-28 1991-09-23 Analogues de camptothecine solubles dans l'eau, procedes et methodes

Publications (2)

Publication Number Publication Date
SK25993A3 SK25993A3 (en) 1993-07-07
SK283693B6 true SK283693B6 (sk) 2003-12-02

Family

ID=24358879

Family Applications (1)

Application Number Title Priority Date Filing Date
SK259-93A SK283693B6 (sk) 1990-09-28 1991-09-23 Spôsob prípravy kamptotecínu alebo jeho farmaceuticky prijateľnej soli

Country Status (25)

Country Link
US (1) US5734056A (fr)
EP (1) EP0547165B1 (fr)
JP (1) JP2848958B2 (fr)
CN (1) CN1033509C (fr)
AT (1) ATE186461T1 (fr)
AU (1) AU664830B2 (fr)
CA (1) CA2090967C (fr)
CZ (1) CZ51593A3 (fr)
DE (1) DE69131775T2 (fr)
DK (1) DK0547165T3 (fr)
ES (1) ES2137932T3 (fr)
FI (1) FI931384A (fr)
GR (1) GR3031823T3 (fr)
HK (1) HK1012283A1 (fr)
HU (1) HUT70024A (fr)
IE (1) IE913402A1 (fr)
IL (1) IL99571A (fr)
NO (1) NO931153D0 (fr)
NZ (1) NZ239947A (fr)
PT (1) PT99109B (fr)
SI (1) SI9111599A (fr)
SK (1) SK283693B6 (fr)
WO (1) WO1992005785A1 (fr)
YU (1) YU159991A (fr)
ZA (1) ZA917748B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5527913A (en) * 1993-02-25 1996-06-18 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
KR960029336A (ko) * 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
JPH08333370A (ja) * 1995-06-08 1996-12-17 Kyorin Pharmaceut Co Ltd 水に可溶な新規フルオロエチルカンプトテシン誘導体、及びその製造方法
WO1997019085A1 (fr) * 1995-11-22 1997-05-29 Research Triangle Institute Composes de camptothecine a proprietes combinees d'inhibition de la topoisomerase i et d'alkylation de l'adn
US6407118B1 (en) 1996-01-30 2002-06-18 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
GB9601779D0 (en) * 1996-01-30 1996-04-03 Pharmacia Spa 9, 10 Disubstituted camptothecin derivatives
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2004055020A1 (fr) * 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Procede de preparation directe d'analogues de 5-alcoxy et de 5-acyloxy de camptothecines ou de mappicines cetones
AU2003223109A1 (en) * 2003-03-31 2004-10-25 Council Of Scientific And Industrial Research Process for preparing topotecan from 10-hydroxy-4-(s) camptothecin
US7151179B2 (en) * 2003-05-12 2006-12-19 Scinopharm Taiwan, Ltd. Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin
CZ299329B6 (cs) * 2003-08-26 2008-06-18 Pliva-Lachema A.S. Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
CZ298934B6 (cs) * 2003-08-26 2008-03-12 Pliva- Lachema A.S. Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
TWI333492B (en) * 2003-11-12 2010-11-21 Smithkline Beecham Cork Ltd Crystalline topotecan hydrochloride product and preparation thereof
CZ299593B6 (cs) * 2003-12-16 2008-09-10 Pliva-Lachema A. S. Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
US20050267141A1 (en) 2004-05-28 2005-12-01 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives
US20050272757A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
WO2006016203A1 (fr) * 2004-08-09 2006-02-16 Shilpa Medicare Limited Procédé amélioré de preparation de chlorhydrate trihydraté d'irinotécan
JP4891912B2 (ja) * 2004-11-05 2012-03-07 サムヤン コーポレイション 非水性極性溶媒中の１０−ヒドロキシカンプトテシン化合物の溶解度を増加させるための薬剤製剤
US20060135546A1 (en) * 2004-12-16 2006-06-22 Jagadevappa Basavaraja Methods for the purification of 20(S)- camptothecin
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
US8349863B2 (en) * 2005-10-10 2013-01-08 Cipla Limited Crystalline polymorphic form of a camptothecin analogue
US7547785B2 (en) 2005-12-26 2009-06-16 Dr. Reddy's Laboratories Limited Process for preparing topotecan
WO2007127839A2 (fr) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions et méthodes pour l'administration de neurothérapeutiques de haut poids moléculaire améliorée par convection
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
CA2655257A1 (fr) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Procede permettant de traiter des maladies avec des inhibiteurs de parp
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080039485A1 (en) * 2006-08-08 2008-02-14 Targetgen Biotechnology Co., Ltd. Low-dose-long-term pharmaceutical composition comprising camptothecin derivatives for the treatment of cancers
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
WO2008030891A2 (fr) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition de la synthèse d'acides gras au moyen d'inhibiteurs parp et méthodes de traitement associées
CA2662517A1 (fr) * 2006-09-05 2008-03-13 Jerome Moore Traitement du cancer
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
US7977483B2 (en) 2007-04-11 2011-07-12 Scinopharm Taiwan, Ltd. Process for making topotecan
JP2011500684A (ja) * 2007-10-19 2011-01-06 バイパー サイエンシズ，インコーポレイティド ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物
CA2703489A1 (fr) 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. Derive de dihydropyrazolopyrimidinone substitue par pyridone
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CN101918003A (zh) * 2007-11-12 2010-12-15 彼帕科学公司 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌
ITMI20072268A1 (it) 2007-12-04 2009-06-05 Antibioticos Spa Polimorfi cristallini di topotecan cloridrato con elevato grado di purezza e metodi per la loro preparazione
MX2010006154A (es) * 2007-12-07 2010-09-24 Bipar Sciences Inc Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa.
CN101450949B (zh) * 2007-12-07 2011-10-05 上海龙翔生物医药开发有限公司 一种10-羟基喜树碱的化学半合成工艺
CN102046634B (zh) 2008-05-29 2013-04-24 日本迈科洛生物制药有限公司 喜树碱衍生物的制备方法
CA2750716A1 (fr) 2009-02-25 2010-09-02 Msd K.K. Derive de pyrimido-pyrimido-indazole
EP2403339B1 (fr) 2009-03-06 2017-01-18 Merck Sharp & Dohme Corp. Thérapie de combinaison anti-cancer avec un inhibiteur de akt et d'autres agents anti-cancer
JP6013359B2 (ja) 2010-12-17 2016-10-25 ノバルティス アーゲー 組合せ
WO2012106302A1 (fr) 2011-02-01 2012-08-09 Glaxo Wellcome Manufacturing Pte Ltd Association
CN103145720B (zh) * 2013-02-20 2015-09-30 上海北卡医药技术有限公司 一种10-羟基喜树碱的一水合物的制备方法
EP2881396A1 (fr) * 2013-12-03 2015-06-10 Synbias Pharma AG Procédé pour la synthèse de l'irinotécan
WO2021173773A1 (fr) 2020-02-25 2021-09-02 Mediboston, Inc. Dérivés de camptothécine et leurs utilisations
WO2023220641A2 (fr) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Méthodes et utilisations associées à une thérapie par lymphocytes t et leur production

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS595188A (ja) * 1982-06-30 1984-01-12 Yakult Honsha Co Ltd １０−ヒドロキシカンプトテシンの製造法
JPS5946284A (ja) * 1982-09-10 1984-03-15 Yakult Honsha Co Ltd １１−ニトロカンプトテシン誘導体およびその製造法
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) * 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
HU213136B (en) * 1990-08-14 1997-02-28 Kyorin Seiyaku Kk Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them
US5352789A (en) * 1993-02-25 1994-10-04 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds

Also Published As

Publication number Publication date
YU159991A (sh) 1994-06-10
EP0547165A4 (fr) 1994-03-30
CA2090967C (fr) 2007-02-06
PT99109A (pt) 1992-08-31
ZA917748B (en) 1992-09-30
CN1062731A (zh) 1992-07-15
FI931384A0 (fi) 1993-03-26
HK1012283A1 (en) 1999-07-30
CZ51593A3 (en) 1994-01-19
IL99571A0 (en) 1992-08-18
DE69131775T2 (de) 2000-04-20
IE913402A1 (en) 1992-04-08
EP0547165B1 (fr) 1999-11-10
AU664830B2 (en) 1995-12-07
FI931384A (fi) 1993-03-26
AU8739991A (en) 1992-04-28
EP0547165A1 (fr) 1993-06-23
US5734056A (en) 1998-03-31
SI9111599A (sl) 1998-02-28
NZ239947A (en) 1994-07-26
ATE186461T1 (de) 1999-11-15
NO931153L (no) 1993-03-26
ES2137932T3 (es) 2000-01-01
WO1992005785A1 (fr) 1992-04-16
JPH06501476A (ja) 1994-02-17
HUT70024A (en) 1995-09-28
DE69131775D1 (de) 1999-12-16
NO931153D0 (no) 1993-03-26
DK0547165T3 (da) 2000-03-27
CN1033509C (zh) 1996-12-11
SK25993A3 (en) 1993-07-07
PT99109B (pt) 1999-02-26
GR3031823T3 (en) 2000-02-29
CA2090967A1 (fr) 1992-03-29
IL99571A (en) 2000-08-31
JP2848958B2 (ja) 1999-01-20
HU9300878D0 (en) 1993-06-28

Similar Documents

Publication Publication Date Title
SK283693B6 (sk) Spôsob prípravy kamptotecínu alebo jeho farmaceuticky prijateľnej soli
EP0266349B1 (fr) Derives d'indole tricycliques, fabrication et utilisation comme medicaments
EP0046666B1 (fr) 2(3H)-Indolones, procédé de préparation et compositions les contenant
DE69521266T2 (de) Verfahren zur herstellung von 9-amino camptothecin
Lucas et al. Rauwolfia Alkaloids. XXXI. 1 The Synthesis and Activity of Some Reserpine Analogs2
JPH02111776A (ja) 四環式抗うつ剤
DE69814667T2 (de) Camptothecin-derivate
EP0824534A1 (fr) Derives de camptothecine 9,10 disubstituee dotes d'une activite antitumorale
CA1263390A (fr) Derives de 3-(acylaminomethyl)imidazol[1,2-a] pyridine; preparation et utilisation comme agents therapeutiques
CA2278845C (fr) Processus de preparation d'acides carboxyliques de quinolone et de naphthyridone
US4218479A (en) Novel benzylalcohols and pharmaceutical compositions and use thereof
US3910937A (en) Certain bis-(hydroxyalkyl)esters of 1,4-dihydro-2,6-diloweralkyl-4-(2-trifluoromethylphenyl)pyridine-3, 5 dicarboxylic acid and the N-methyl derivative thereof
EP0170549B1 (fr) Dérivés de tétrahydro-4,5,6,7 furo ou 1H-pyrrolo[2,3-c]pyridine, leur préparation et leur application en therapeutique
EP0101633B1 (fr) Esters pyridinecarboxyliques de dopamine et de ses dérivés N-alkylés
SU1095878A3 (ru) Способ получени производных 1-(4-арилциклогексил)пиперидина или их фармацевтически пригодных солей или их стереоизомерных форм
US5686614A (en) Preparation of chiral 5-aminocarbonyl-5H-dibenzo a,d!cyclohepten-5,10-imines by optical resolution
CN114105974A (zh) 一种唑吡坦的制备方法
JP5238493B2 (ja) カンプトテシン誘導体の製造方法
KR820000494B1 (ko) 퀴나졸린 유도체의 제조방법
EP0707579B1 (fr) Methanoanthracenes substitues de piperidinyle en tant qu'antagonistes de d1/d2 et en tant qu'antagonistes de serotonine de 5ht2
JPH04364186A (ja) スタウロスポリン誘導体および該化合物を有効成分とする血小板凝集阻害剤

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20110923